We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+13.86%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$421M
AUM Growth
+$85.4M
Cap. Flow
+$55.9M
Cap. Flow %
13.26%
Top 10 Hldgs %
50.23%
Holding
96
New
22
Increased
24
Reduced
22
Closed
7

Top Buys

Rank Stock Value
1
NRIX icon
Nurix Therapeutics
NRIX
+$11.6M
2
RVMD icon
Revolution Medicines
RVMD
+$5.77M
3
PLX icon
Protalix BioTherapeutics
PLX
+$5.61M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.51M
5
ACET icon
Adicet Bio
ACET
+$4.41M

Top Sells

Rank Stock Value
1
FLNA
Filana Therapeutics
FLNA
+$3.07M
2
STIM icon
Neuronetics
STIM
+$2.91M
3
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$2.9M
4
AGTC
Applied Genetic Technologies Corporation
AGTC
+$2.46M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 90.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
51
Sutro Biopharma
STRO
$400M
$1.94M 0.46%
8,500
– –
APLS
52
DELISTED
Apellis Pharmaceuticals
APLS
$1.93M 0.46%
44,926
+1,010
+2% +$47.8K
BWAY
53
Brainsway
BWAY
$628M
$1.81M 0.43%
+400,000
New +$1.73M
LONA
54
LeonaBio Inc
LONA
$73.4M
$1.68M 0.4%
9,153
+7,500
+454% +$1.65M
KNTE
55
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$1.65M 0.39%
52,915
-15,206
-22% -$530K
CGEN icon
56
Compugen
CGEN
$218M
$1.62M 0.39%
189,002
+73,800
+64% +$818K
RCUS icon
57
Arcus Biosciences
RCUS
$3.61B
$1.62M 0.38%
57,600
+8,000
+16% +$278K
LQDA icon
58
Liquidia Corp
LQDA
$7.95B
$1.55M 0.37%
575,000
– –
JNJ icon
59
Johnson & Johnson
JNJ
$619B
$1.54M 0.37%
9,400
– –
KDMN
60
DELISTED
Kadmon Holdings, Inc.
KDMN
$1.53M 0.36%
394,561
-75,800
-16% -$347K
CBAY
61
DELISTED
Cymabay Therapeutics
CBAY
$1.53M 0.36%
+337,770
New +$1.82M
KALV
62
DELISTED
KalVista Pharmaceuticals
KALV
$1.5M 0.36%
+58,600
New +$1.54M
INFI
63
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.48M 0.35%
+459,260
New +$1.53M
KURA icon
64
Kura Oncology
KURA
$824M
$1.46M 0.35%
51,800
+42,800
+476% +$1.35M
CFMS
65
DELISTED
Conformis, Inc. Common Stock
CFMS
$1.29M 0.31%
+52,000
New +$1.4M
SNDX icon
66
Syndax Pharmaceuticals
SNDX
$1.76B
$1.29M 0.31%
57,500
+47,500
+475% +$1.07M
ALPN
67
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.2M 0.28%
113,302
+100
+0.1% +$1.25K
LRMR icon
68
Larimar Therapeutics
LRMR
$436M
$1.19M 0.28%
81,432
+33,004
+68% +$600K
TPTX
69
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$994K 0.24%
+10,509
New +$1.25M
OTIC
70
DELISTED
Otonomy, Inc.
OTIC
$993K 0.24%
389,592
– –
RIGL icon
71
Rigel Pharmaceuticals
RIGL
$733M
$942K 0.22%
+27,550
New +$1.09M
GNFT
72
DELISTED
Genfit
GNFT
$871K 0.21%
188,549
+74,208
+65% +$382K
TBPH icon
73
Theravance Biopharma
TBPH
$877M
$840K 0.2%
+41,165
New +$782K
INGN icon
74
Inogen
INGN
$176M
$788K 0.19%
15,000
– –
SCYX icon
75
SCYNEXIS
SCYX
$51.6M
$714K 0.17%
11,234
-13,766
-55% -$903K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, DAFNA Capital Management held 96 positions worth $421M, up 25% from $336M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management deployed $55.9M of net new capital in Q1 2021, opening 22 new positions and adding to 24 existing holdings. Its largest new stake was Nurix Therapeutics: 306,320 shares worth $9.52M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier.

On the sell side, the largest reduction was Neuronetics, an estimated $2.91M trimmed.

  • DAFNA Capital Management's largest Q1 2021 buy was Nurix Therapeutics: 306,320 shares worth $9.52M.
  • DAFNA Capital Management added most to Revolution Medicines in Q1 2021, an estimated $5.77M increase.
  • DAFNA Capital Management's biggest Q1 2021 reduction was Neuronetics, cutting an estimated $2.91M.
  • DAFNA Capital Management fully exited Filana Therapeutics in Q1 2021, selling an estimated $3.07M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $421M portfolio in Q1 2021.
  • DAFNA Capital Management opened 22 new positions and closed 7 in Q1 2021.
  • DAFNA Capital Management's portfolio value rose 25% quarter-over-quarter to $421M.

Based on DAFNA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.